We are contacting you regarding our ongoing investigation into aquaculture and the global fishmeal and fish oil industry, which has uncovered an array of industry-wide environmental and human rights concerns. These concerns date from between 2018 and the present, and they pertain to events or conditions on land or at sea.
Our investigation has found that in 2021, the Federal Trade Commission (FTC) charged BASF and Diem Labs, a Michigan-based dietary supplement manufacturer, with falsely claiming that two dietary fish oil supplements were clinically proven to treat liver disease. The FTC said…
BASF acknowledges and has fully complied with the May 25, 2021 Consent Order issued by the U.S. Federal Trade Commission (FTC) regarding the marketing of its now-discontinued Hepaxa™ and Hepaxa™ PD products. In accordance with applicable law and effective product stewardship, BASF provides substantiation in the form of competent and reliable scientific evidence for all health benefit claims for its wide array of pharmaceutical and nutritional products.
If you have any additional questions, feel free to reach out.